ASH2023注目テーマ⑥ 注目演題「#4」

移植適応新規MMに対する、
Isa-KRd療法による導入療法と地固め療法 Results of the Phase III Randomized Iskia Trial: Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone Vs Carfilzomib-Lenalidomide-Dexamethasone As Pre-Transplant Induction and Post-Transplant Consolidation in Newly Diagnosed Multiple Myeloma Patients (#4)

Francesca Gay（Division of Hematology, Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy）